Associations - EGFR T790M

EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	lazertinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	almonertinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	erlotinib Sensitive: B - Late Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: B - Late Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: B - Late Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: B - Late Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	osimertinib Resistant: C1 - Off-label
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	rociletinib Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	ASP8273 Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	ASK120067 Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib + ramucirumab Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	olmutinib Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	lazertinib Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	anlotinib Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	AST2818 Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	AC0010MA Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	D-0316 Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 inhibitor Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	bevacizumab + osimertinib Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Cancer Lung Cancer	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	APL-103 Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	WZ4002 Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	gefitinib Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	erlotinib Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	imatinib Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	afatinib + ruxolitinib Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	cetuximab + brigatinib Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	afatinib Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	osimertinib + ramucirumab Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	bevacizumab + erlotinib Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	bevacizumab + gefitinib Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Gallbladder Cancer Gallbladder Cancer	erlotinib Sensitive: C4 – Case Studies
EGFR T790M EGFR T790M	Pancreatic Cancer Pancreatic Cancer	erlotinib Resistant: C4 – Case Studies
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	APG-1252 Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib + DC101 Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	amivantamab-vmjw Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	gefitinib + PF-03084014 Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	MTI-31 Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	neratinib + PF-05212384 Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	neratinib Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Lung Cancer Lung Cancer	BMS-722782 Sensitive: D – Preclinical
EGFR T790M EGFR T790M	Lung Cancer Lung Cancer	EGFR inhibitor Resistant: D – Preclinical